Skip to main content

Table 2 RNA based biomarkers used in follow-up for non muscle invasive bladder cancer patients

From: Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review

Reference Patients/samples Recurrence rate Sensitivity Specificity NPV PPV AUC Method Markers
Sapre et al 2016 [29] 131/131 NA 88 48 75 63 0.74 miRNA PCR 6 miRNA signaturea
Kavalieris et al 2017 [30] 736/1036 15.1% 92 NA 96 NA 0.73 mRNA PCR 5 genes mRNA expression (Cx Bladder Monitor® )b
Lotan et al 2017 [31] 748/1016 14.8% 91
95 (HG)
NA 96 NA NA mRNA PCR 5 genes mRNA expression (Cx Bladder Monitor® )b vs NMP22 ELISA vs NMP22 BladderChek
Pilcher et al 2018 [32] 140/155 30.7% 84
100 (HG)
91 93 72 0.87 mRNA RT-PCR ABL1, CRH, IGF2, UPK1B, ANXA10 (Xpert Bladder Cancer Monitor®)
Wallace et al 2018 [33] 370/370 13.2% 73
83 (HG)
77 92 44 0.87 mRNA RT-qPCR ABL1, CRH, IGF2, ANXA10, UPK1B (Xpert Bladder Cancer Monitor®)
  1. HG high grade, NA not allowed
  2. amiR16, miR200c, miR205, miR21, miR221 and miR34a
  3. bIGFBP5, HOXA13, MDK, CDK1, CXCR2